Editorial: fixed‐dose combination calcipotriol/betamethasone dipropionate foam in the treatment of patients with psoriasis

por Lebwohl, M., Warren, R.B.
Publicado 2021

Addressing challenges associated with long‐term topical treatment and benefits of proactive management in patients with psoriasis

por Lebwohl, M., Thaçi, D., Warren, R.B.
Publicado 2021

Safety of selective IL‐23p19 inhibitors for the treatment of psoriasis

por Crowley, J.J., Warren, R.B., Cather, J.C.
Publicado 2019

The role of the interleukin‐23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis

por Egeberg, A., Gisondi, P., Carrascosa, J.M., Warren, R.B., Mrowietz, U.
Publicado 2020

Secukinumab significantly reduces psoriasis‐related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom

por Warren, R.B., Halliday, A., Graham, C.N., Gilloteau, I., Miles, L., McBride, D.
Publicado 2018

Switching from a fumaric acid ester mixture to dimethylfumarate monotherapy in psoriasis

por Warren, R.B., Barker, J.N.W., Van de Kerkhof, P., Reich, K., Mrowietz, U.
Publicado 2019

Efficacy and safety of risankizumab vs. secukinumab in patients with moderate‐to‐severe plaque psoriasis (IMMerge): results from a phase III, randomized, open‐label, efficacy–asses...

por Warren, R.B., Blauvelt, A., Poulin, Y., Beeck, S., Kelly, M., Wu, T., Geng, Z., Paul, C.
Publicado 2020

Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta‐analysis of randomized controlled trials

por Rungapiromnan, W., Yiu, Z.Z.N., Warren, R.B., Griffiths, C.E.M., Ashcroft, D.M.
Publicado 2017

Network meta‐analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method

por Mrowietz, U., Warren, R.B., Leonardi, C.L., Saure, D., Petto, H., Hartz, S., Dossenbach, M., Reich, K.
Publicado 2021

A novel mutation in IL36RN underpins childhood pustular dermatosis

por Ellingford, J.M., Black, G.C.M., Clayton, T.H., Judge, M., Griffiths, C.E.M., Warren, R.B.
Publicado 2015

Three‐year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial

por Warren, R. B., Lebwohl, M., Sofen, H., Piguet, V., Augustin, M., Brock, F., C. Arendt, Fierens, F., Blauvelt, A.
Publicado 2021

Risk of COVID‐19 infection in adult patients with atopic eczema and psoriasis: a single‐centre cross‐sectional study

por Yiu, Z.Z.N., Harding‐Oredugba, G., Griffiths, C.E.M., Warren, R.B., McMullen, E., Hunter, H.J.A.
Publicado 2021

Antibody responses to single‐dose SARS‐CoV‐2 vaccination in patients receiving immunomodulators for immune‐mediated inflammatory disease

por Al‐Janabi, A., Littlewood, Z., Griffiths, C.E.M., Hunter, H.J.A., Chinoy, H., Moriarty, C., Yiu, Z.Z.N., Warren, R.B.
Publicado 2021

Long‐term, durable, absolute Psoriasis Area and Severity Index and health‐related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patien...

por Gooderham, M., Pinter, A., Ferris, L.K., Warren, R.B., Zhan, T., Zeng, J., Soliman, A.M., Kaufmann, C., Kaplan, B., Photowala, H., Strober, B.
Publicado 2022

Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis

por Iskandar, I.Y.K., Ashcroft, D.M., Warren, R.B., Lunt, M., McElhone, K., Smith, C.H., Reynolds, N.J., Griffiths, C.E.M.
Publicado 2017

Long‐term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3‐year results from two randomized phase III trials (CIMPASI‐1 and CIMPASI‐2)

por Gordon, K.B., Warren, R.B., Gottlieb, A.B., Blauvelt, A., Thaçi, D., Leonardi, C., Poulin, Y., Boehnlein, M., Brock, F., Ecoffet, C., Reich, K.
Publicado 2020

Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study

por Rungapiromnan, W., Mason, K.J., Lunt, M., McElhone, K., Burden, A.D., Rutter, M.K., Warren, R.B., Griffiths, C.E.M., Ashcroft, D.M.
Publicado 2019

Long‐term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo‐controlled studies

por Blauvelt, A., Paul, C., van de Kerkhof, P., Warren, R.B., Gottlieb, A.B., Langley, R.G., Brock, F., Arendt, C., Boehnlein, M., Lebwohl, M., Reich, K.
Publicado 2020

Development and validation of a multivariable risk prediction model for serious infection in patients with psoriasis receiving systemic therapy

por Yiu, Z.Z.N., Sorbe, C., Lunt, M., Rustenbach, S.J., Kühl, L., Augustin, M., Mason, K.J., Ashcroft, D.M., Griffiths, C.E.M., Warren, R.B.
Publicado 2019

Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study

por Warren, R.B., Marsden, A., Tomenson, B., Mason, K.J., Soliman, M.M., Burden, A.D., Reynolds, N.J., Stocken, D., Emsley, R., Griffiths, C.E.M., Smith, C.
Publicado 2018